Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far
Reviewed 19 sourcesPublished by PepVault
Olatorepatide (HS-20094) is a weekly GLP-1/GIP shot from Hansoh, licensed to Regeneron: the 19.3% phase 3 result, every trial, and when US data is due.

- Last reviewed
- Sources
- 19
- Questions
- 6
- Compounds
- 2
The short answer
Olatorepatide (code name HS-20094) is a once-weekly GLP-1/GIP injection, the same drug class as Zepbound. China's Hansoh Pharma invented it and Regeneron holds the rights outside China. In Hansoh's 48-week phase 3 trial in 604 Chinese adults, weight fell 19.3% on the 15 mg dose, against 2.7% on placebo. It is approved nowhere; Regeneron's US trials are under way.
Evidence: Early to mid-stage: one completed phase 3 trial in Chinese adults, reported in Hansoh's conference releases with no journal paper yet, plus small phase 2 diabetes data; Regeneron's US trials have no results. Approved nowhere.

What is olatorepatide?
Olatorepatide is an experimental weight-loss and diabetes injection taken once a week. It switches on two hormone receptors at once: GLP-1 and GIP, the two gut hormones that help set appetite and blood sugar after a meal. That makes it a dual agonist, the class tirzepatide (Zepbound, Mounjaro) opened.
Hansoh Pharma, a Shanghai drug company, discovered it in house and ran its trials as HS-2009426. Olatorepatide is its generic name, the international nonproprietary name (INN) the World Health Organization proposed in List 130, which names it a dual GIP and GLP-1 receptor agonist1. Regeneron, the New York company best known for Dupixent and Eylea, uses the INN and lists the drug as in-licensed from Hansoh4.
The deal was announced on June 2, 2025: Regeneron took the rights everywhere except mainland China, Hong Kong and Macau for $80 million up front, with up to $1.93 billion more in milestone payments and double-digit royalties on sales2. Regeneron's filings say the license took effect in July 2025 and the royalty is low double-digit34. Hansoh keeps China, where its application for approval was accepted for review in June 20269.

How does olatorepatide work?
Like tirzepatide, it lowers appetite so people eat less, slows how fast the stomach empties and helps the pancreas release insulin10. The WHO entry shows how closely it is built on the same plan118:
- A chain of 40 amino acids, one longer than tirzepatide's 39, with the same unusual second building block tirzepatide uses (Aib), which helps the peptide resist the enzyme that breaks down the body's own GLP-1 within minutes118.
- A 20-carbon fatty acid fixed to its last amino acid through a short linker. Tirzepatide carries the same fatty acid on its 20th amino acid, and there it makes the drug ride on albumin, a blood protein, so the body clears it slowly; olatorepatide's tail is built for the same job118.
- A half-life of about six to seven days, the time the body takes to clear half a dose: 142 to 168 hours in Hansoh's early diabetes trial10, against about five to six days for tirzepatide18. That is what makes one shot a week enough.
Hansoh calls olatorepatide "dual-biased"7. A biased agonist switches a receptor on in a chosen way, usually sending the receptor's main signal while pulling in less of beta-arrestin, the protein that dulls a receptor and draws it into the cell. Hansoh presents the design as the way olatorepatide pairs strong weight loss with easier tolerability7; it has not published which signals the drug favours, so the claim stands as the company's.
How much weight did people lose on olatorepatide?
Up to 19.3% in 48 weeks, and still falling. LIGHTEN, Hansoh's phase 3 trial, gave 604 Chinese adults a weekly shot of 5, 10 or 15 mg or placebo for 48 weeks; people qualified with a BMI of 28 or more, or 24 to 28 with a weight-related condition711. Of them, 90.1% finished the full 48 weeks, and up to 97.2% of those on the drug lost at least 5% of their weight67. The trial met both of its main goals, average weight change and the share who lost at least 5%6.
| LIGHTEN, week 48 | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Weight change, while on treatment7 | -2.7% | -12.5% | -17.5% | -19.3% |
| Weight change, counting everyone who started7 | -2.5% | -11.8% | -17.0% | -18.7% |
The two weight rows answer different questions. The first follows people while they kept taking the drug; the second counts everyone who started, including those who stopped, which is closer to real life. On 15 mg the waist shrank by 16.0 cm on average. Hansoh reports that the weight curve had not flattened at week 487, and that blood pressure, blood fats, HbA1c (the three-month blood sugar average) and insulin resistance improved too7.
The fairest yardstick is tirzepatide's own trial in China. SURMOUNT-CN enrolled Chinese adults on the same BMI rules, without diabetes, for 52 weeks: weight fell 17.5% on 15 mg tirzepatide and 2.3% on placebo, counting everyone17. Olatorepatide reached 18.7% by the same count four weeks sooner, 16.2 points beyond its placebo against tirzepatide's 15.2. Our reading: in Chinese adults it is level with tirzepatide or a little ahead. The two were never tested against each other, so this is a close call, not a verdict.
A sex-subgroup analysis shown at ObesityWeek on November 14, 2026, found that women did numerically better than men on weight, waist, waist-to-height ratio and a fatty-liver score, and more of them reached 15% and 20% weight loss8. Hansoh has not yet published LIGHTEN in a journal; the numbers above come from its conference releases.
PepVault keeps your weekly shot and your weigh-ins side by side, so your own trend line is there to compare with any trial's. Track your weight in PepVault
What side effects did olatorepatide cause?
The usual ones for this class, in the stomach and gut, and at well under the rates tirzepatide showed in its own trial in Chinese adults. Olatorepatide's figures are averaged across the three LIGHTEN doses7; tirzepatide's are the range across its 10 and 15 mg doses in SURMOUNT-CN17:
| Side effect | Olatorepatide, LIGHTEN7 | Placebo, LIGHTEN7 | Tirzepatide, SURMOUNT-CN17 | Placebo, SURMOUNT-CN17 |
|---|---|---|---|---|
| Nausea | 7.8% | 2.6% | 30.0% to 32.4% | 5.8% |
| Vomiting | 4.9% | 2.0% | 11.4% to 19.7% | 4.3% |
| Diarrhea | 16.9% | 7.8% | 40.0% to 40.8% | 8.7% |
| Constipation | 5.1% | 1.3% | Under 10% | Under 10% |
No one in LIGHTEN stopped treatment or left the trial early because of a side effect judged to be caused by olatorepatide7; in SURMOUNT-CN, 2.9% to 7.0% stopped tirzepatide for a side effect17. Nausea came in 9.0% of women and 5.0% of men on olatorepatide8. Zepbound's US label, from trials mostly outside China, lists nausea at 25% to 29%18. The gap is wide, and Regeneron's US trials will show whether it holds in a different population.
When to get help On any GLP-1 drug, severe stomach pain that will not ease, sometimes reaching the back, or vomiting that stops you keeping fluids down is a reason to call your clinician the same day18.
Which olatorepatide trials are in the registry?
Twelve records name it under either name as of November 20, 2026, eight sponsored by Hansoh in China and four by Regeneron, whose three trials with sites listed are all in the United States16. Dates are primary completion, per ClinicalTrials.gov: when the main measurement ends, not when results come out. "Est." marks the sponsor's estimate.
| Trial | Phase | People | Primary completion | Status |
|---|---|---|---|---|
| Regeneron, US: weight, safety and blood levels (NCT07431086)12 | 2 | 120 | Nov 13, 2026 (est.) | Active, not recruiting |
| Regeneron, US: doses and step-up schedules, 52 weeks (NCT07685808)13 | 2 | 360 (planned) | Jan 2028 (est.) | Recruiting |
| Regeneron, hidradenitis suppurativa with obesity (NCT07830329)15 | 2 | 300 (planned) | Nov 2028 (est.) | Recruiting |
| Regeneron, RISE-1: obesity without diabetes, 72 weeks (NCT07896265)14 | 3 | 3,000 (planned) | Dec 2028 (est.) | Not yet recruiting |
| Hansoh, LIGHTEN: obesity, China (NCT06839664)11 | 3 | 604 | Jan 2026 | Completed |
| Hansoh, type 2 diabetes vs dulaglutide, China (NCT07156539) | 3 | 546 (planned) | Mar 2027 (est.) | Not yet recruiting (record from Sep 2025) |
| Hansoh, type 2 diabetes on diet and exercise, China (NCT07156500) | 3 | 204 (planned) | Mar 2027 (est.) | Not yet recruiting (record from Sep 2025) |
| Hansoh, obesity, 24 weeks, China (NCT06118021) | 2 | 200 | Aug 2024 | Completed, no results posted |
| Hansoh, type 2 diabetes vs dulaglutide, 32 weeks, China (NCT06901648) | 2 | 275 | Mar 2025 | Completed, no results posted |
| Hansoh, type 2 diabetes, 4 weeks, China (NCT06118008)10 | 2 | 54 | Jan 2024 | Completed |
| Hansoh, two pen types, China (NCT07057674) | 1 | 144 (planned) | Feb 2026 (est.) | Recruiting (record from Jul 2025) |
| Hansoh, first human trial, China (NCT05116410) | 1 | 68 (planned) | Oct 2022 (est.) | Unknown |
Regeneron's first US trial is a small one: its main measures are safety and how much drug is in the blood at weeks 15 and 24, with weight change at week 25 as a secondary measure12. It is the first look at olatorepatide in people outside China. RISE-1, the first Regeneron phase 3, measures weight change at 72 weeks, the length of SURMOUNT-1, the trial behind Zepbound's approval1418. Hidradenitis suppurativa, the third trial's target, is a skin disease of painful lumps and abscesses in the armpits and groin; that trial enrolls people who also live with overweight or obesity and counts the lumps at 52 weeks15.
Regeneron also plans olatorepatide as the base of combination shots. It said in January 2026 that it would start a program pairing it with Praluent, its LDL cholesterol drug, because GLP-1 drugs alone lower LDL cholesterol by less than 10%5; no such trial is in the registry yet16. Separately, Regeneron tests its muscle antibodies trevogrumab and garetosmab with semaglutide, not with olatorepatide19.
When is the next olatorepatide data due?
The first US numbers can come first. NCT07431086 has an estimated primary completion of November 13, 2026, and an estimated study completion of December 18, 202612; Regeneron has not said when it will report it. In China, approval is the next step: the drug's application for long-term weight management was accepted for review by China's drug regulator in June 20269. Hansoh's two diabetes phase 3 trials estimate March 202716.
Outside China, the answer is years away. In its October 30, 2026 filing, Regeneron said it expects to start its phase 3 program in obesity without type 2 diabetes in the fourth quarter of 2026 and with type 2 diabetes in the first half of 20274. The registry estimates that RISE-1's main measurement ends in December 202814, so a US filing would follow that.
Has the US trial reported yet? Not as of November 20, 2026: the registry shows no results, and Regeneron's October filing gives no date412. This page is updated when it lands.
If you take a weekly GLP-1 today, PepVault logs each shot and reminds you on the day it falls due, so any later switch starts from your own record. Log it in PepVault
Sources
- World Health Organization. Proposed INN: List 130 (olatorepatide). WHO Drug Information, Vol. 37, No. 4, 2023. cdn.who.int
- Hansoh Pharma. Hansoh Pharma grants Regeneron an exclusive license to its investigational dual GLP-1/GIP receptor agonist HS-20094. June 2, 2025. hansoh.cn
- Regeneron Pharmaceuticals. Quarterly report on Form 10-Q for the quarter ended June 30, 2025 (the Hansoh license). SEC EDGAR. sec.gov
- Regeneron Pharmaceuticals. Quarterly report on Form 10-Q for the quarter ended September 30, 2026 (olatorepatide milestones). SEC EDGAR. sec.gov
- Regeneron Pharmaceuticals. J.P. Morgan Healthcare Conference presentation (Form 8-K, Exhibit 99.1). January 12, 2026. sec.gov
- Hansoh Pharma. Olatorepatide (HS-20094) achieves up to 19.3% weight loss at week 48 in phase 3 study. March 7, 2026. hansoh.cn
- Hansoh Pharma. EASD 2026: phase III (LIGHTEN) data of olatorepatide presented as a late-breaking oral presentation. October 2, 2026. hansoh.cn
- Hansoh Pharma. ObesityWeek 2026: olatorepatide phase III LIGHTEN sex-subgroup data. November 16, 2026. hansoh.cn
- Hansoh Pharma. New drug application for olatorepatide injection accepted by the National Medical Products Administration. June 4, 2026. hansoh.cn
- Hansoh Pharma. 2024 ADA: phase II data of HS-20094 in type 2 diabetes (NCT06118008; poster 733-P). July 3, 2024. hansoh.cn
- ClinicalTrials.gov. NCT06839664: a study of HS-20094 in Chinese adults with overweight or obesity (LIGHTEN). Jiangsu Hansoh Pharmaceutical. clinicaltrials.gov
- ClinicalTrials.gov. NCT07431086: olatorepatide in adults with overweight or obesity in the US. Regeneron Pharmaceuticals. clinicaltrials.gov
- ClinicalTrials.gov. NCT07685808: olatorepatide with different doses and titration schedules in adults with overweight or obesity. Regeneron Pharmaceuticals. clinicaltrials.gov
- ClinicalTrials.gov. NCT07896265: RISE-1, olatorepatide in adults with overweight or obesity without diabetes. Regeneron Pharmaceuticals. clinicaltrials.gov
- ClinicalTrials.gov. NCT07830329: olatorepatide in moderate to severe hidradenitis suppurativa with overweight or obesity. Regeneron Pharmaceuticals. clinicaltrials.gov
- ClinicalTrials.gov. All studies naming olatorepatide or HS-20094, read November 20, 2026. clinicaltrials.gov
- Zhao L et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024. PubMed 38819983
- Zepbound (tirzepatide) prescribing information. Eli Lilly. DailyMed. dailymed.nlm.nih.gov
- Regeneron Pharmaceuticals. Fourth quarter and full year 2025 results, with 2026 milestones (Form 8-K, Exhibit 99.1). January 30, 2026. sec.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.